Eli Lilly and Company

The University of North Carolina at Chapel Hill

Biogen Idec Ma Inc.

Stephen John Demarest

Xiufeng Wu

Brian Arthur Kuhlman

Scott Glaser

Alexey Alexandrovich Lugovskoy

Brian Miller

Lisa Croner

William Brian Snyder

Raheleh Toughiri

Norman Wang

Steven Morgan Lewis

Andrew Philip Leaver-Fay

Karen Jean Froning

Ellen A Garber

Christilyn Graff

Christopher L Reyes

Kandasamy Hariharan

Shane Krummen Atwell

Hector Aldaz

Derrick Ryan Witcher

Yang Shen

Robert Jan Benschop

Juqun Shen

Yiqing Feng

Stephanie Marie Truhlar

Diana Isabel Ruiz

Payal Mehta

Scott Charles Potter

Anja Koester

The present invention provides fully IgG bi-specific antibodies comprising designed residues in the interface of the heavy chain-heavy chain (C3/C3) domains, processes for preparing said fully IgG bi-specific antibodies, and nucleic acids, vectors and host cells encoding the same.

IgG bispecific antibodies and processes for preparation

The present invention relates to bispecific antibodies that antagonize human PD-1 and agonize human CD137, and may be useful for treating solid and hematological tumors alone and in combination with chemotherapy and ionizing radiation.

Bispecific antibodies targeting immune checkpoints

Methods for producing Fabs and IgG bi-specific antibodies comprising expressing nucleic acids encoding designed residues in the CH1/CL interface are provided. Also provided are Fabs and IgG bi-specific antibodies produced according to the provided methods as well as nucleic acids, vectors and host cells encoding the same.

Methods for producing fabs and IgG bispecific antibodies

The present invention relates to anti-human CD200R agonist antibodies, and uses thereof for treating diseases such as atopic dermatitis, chronic spontaneous urticaria, allergy, asthma, scleroderma, IBD, SLE, MS, RA, GvHD, or psoriasis.

CD200R agonist antibodies and uses thereof

IgG bispecific antibodies are provided that bind human Calcitonin Gene Related Peptide (CGRP) and human Interleukin-23 (IL-23) and are characterized as having high affinity and strong simultaneous neutralizing properties to both human CGRP and human IL-23. The bispecific antibodies of the invention are useful for treating various autoimmune diseases including Inflammatory Bowel Disease, such as Crohn's Disease (CD) and Ulcerative Colitis (UC), and other autoimmune diseases such as psoriatic Arthritis (PsA), ankylosing spondylitis (AS) and atopic dermatitis (AtD). The bispecific antibodies of the invention are useful for treating pain associated with the aforementioned diseases.

Anti-CGRP/anti-IL-23 bispecific antibodies and uses thereof

The present invention provides methods for producing Fabs and bi-specific antibodies comprising designed residues in the interfaces of the heavy chain-light chain variable (V/V) domain and the heavy chain-light chain constant (C/C) domain, Fabs and bi-specific antibodies produced according to said processes and host cells encoding the same.

Methods for producing Fabs and bi-specific antibodies

The present invention provides methods for producing Fabs and bi-specific antibodies comprising designed residues in the interfaces of the heavy chain-light chain variable (V/V) domain and the heavy chain-light chain constant (C/C] domain, Fabs and bi-specific antibodies produced according to said processes and host cells encoding the same.

Methods for producing fabs and bi-specific antibodies

The invention is based, at least in part, on the development of stabilized binding molecules that consist of or comprise a stabilized scFv and methods for making such stabilized molecules.

Stabilized polypeptide compositions

The invention relates to antibodies which bind to insulin like growth factor receptor-1 (IGF-1R) and uses thereof, in particular in the diagnosis and treatment of cancer. Specific human and murine monoclonal antibodies which inhibit IGF-1R-mediated pro-survival and tumor proliferation pathways, and variants, fragments, and derivatives thereof are provided. Also provided are specific human and murine monoclonal antibodies which block the ability of the ligands, insulin like growth factor 1 (IGF-1) and insulin like growth factor 2 (IGF-2) to bind to IGF-1R, as well as fragments, variants and derivatives of such antibodies. The invention also includes polynucleotides encoding the above antibodies or fragments, variants or derivatives thereof, as well as vectors and host cells comprising such polynucleotides. The invention further includes methods of diagnosing and treating cancer using antibodies of the invention.

Anti-IGR-1R antibodies and uses thereof

Anti-IGF-1R antibodies and uses thereof

Growing community of inventors

San Diego, CA, United States of America

Stephen John Demarest